studies

breast cancer - HER2-positive, ... vs. HER inhibitor, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS) (extension)detailed resultsNeoALTTO (lapatinib vs trastuzumab), 2012 0.85 [0.49; 1.47] 0.85[0.49; 1.47]NeoALTTO (lapatinib vs trastuzumab), 201210%303NAnot evaluable events or deaths (EFS) (extended)detailed resultsNeoALTTO (lapatinib vs trastuzumab), 2012 0.98 [0.64; 1.51] 0.98[0.64; 1.51]NeoALTTO (lapatinib vs trastuzumab), 201210%303NAnot evaluable pCR detailed resultsNeoALTTO (lapatinib vs trastuzumab), 2012 0.78 [0.47; 1.30] 0.78[0.47; 1.30]NeoALTTO (lapatinib vs trastuzumab), 201210%303NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-07-01 19:17 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 1309